Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era. [electronic resource]
Producer: 20160505Description: 2047-55 p. digitalISSN:- 1029-2403
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Cyclophosphamide -- administration & dosage
- Doxorubicin -- administration & dosage
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Neoplasm Staging
- Organ Specificity
- Prednisone -- administration & dosage
- Prognosis
- Retrospective Studies
- Rituximab -- administration & dosage
- Survival Rate
- Vincristine -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.